B7-H3 Antibody (G-8): sc-376535
- B7-H3 Antibody (G-8) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against amino acids 166-465 mapping within an N-terminal extracellular domain of B7-H3 of human origin
- recommended for detection of B7-H3 of mouse, rat and human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for B7-H3 Antibody (G-8) for WB applications. These reagents are now offered in bundles with B7-H3 Antibody (G-8) (see ordering information below).
QUICK LINKS
SEE ALSO...
B7-H3 Antibody (G-8) is a mouse monoclonal IgG1 antibody that detects B7-H3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). B7-H3, also known as B7-homolog 3 or B7RP-2, is a member of the B7 Immunoglobulin superfamily and plays a crucial role in the regulation of T cell activation and immune responses. B7-H3 is widely expressed in non-lymphoid tissues, where B7-H3 serves as a costimulatory molecule that enhances the proliferation of both CD4+ and CD8+ T cells. Notably, B7-H3 has been shown to stimulate Th1 and cytotoxic T cell responses, suggesting potential antitumor activity. B7-H3 interactions with receptors may be pivotal in modulating cell-mediated immune responses against cancer, positioning B7-H3 as a promising candidate for therapeutic interventions. B7-H3 monoclonal antibody (G-8) is an essential tool for researchers investigating the complex mechanisms of immune regulation and B7-H3′s potential in cancer therapy.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
B7-H3 Antibody (G-8) References:
- B7-H3: An Attractive Target for Antibody-based Immunotherapy. | Kontos, F., et al. 2021. Clin Cancer Res. 27: 1227-1235. PMID: 33051306
- B7-H3/CD276: An Emerging Cancer Immunotherapy. | Zhou, WT. and Jin, WL. 2021. Front Immunol. 12: 701006. PMID: 34349762
- B7-H3-targeted CAR-T cell therapy for solid tumors. | Li, G., et al. 2022. Int Rev Immunol. 41: 625-637. PMID: 35855615
- B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. | Guo, C., et al. 2023. Eur Urol. 83: 224-238. PMID: 36114082
- Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. | Vitanza, NA., et al. 2023. Cancer Discov. 13: 114-131. PMID: 36259971
- Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. | Zhao, B., et al. 2022. J Hematol Oncol. 15: 153. PMID: 36284349
- New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. | Getu, AA., et al. 2023. Mol Cancer. 22: 43. PMID: 36859240
- B7-H3 immunoregulatory roles in cancer. | Mortezaee, K. 2023. Biomed Pharmacother. 163: 114890. PMID: 37196544
- B7-H3 in Brain Malignancies: Immunology and Immunotherapy. | Guo, X., et al. 2023. Int J Biol Sci. 19: 3762-3780. PMID: 37564196
- Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. | Feng, Y., et al. 2023. Cell Rep. 42: 113503. PMID: 38019654
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
B7-H3 Antibody (G-8) | sc-376535 | 200 µg/ml | $322.00 | |||
B7-H3 Antibody (G-8): m-IgG Fc BP-HRP Bundle | sc-540593 | 200 µg Ab; 10 µg BP | $361.00 | |||
B7-H3 Antibody (G-8): m-IgG1 BP-HRP Bundle | sc-542228 | 200 µg Ab; 20 µg BP | $361.00 |